Incyte's Povorcitinib Shows 71% Response Rate in Late-Stage Hidradenitis Suppurativa Trials
Key Insights
Incyte's experimental drug povorcitinib demonstrated sustained symptom relief in two late-stage trials for moderate to severe hidradenitis suppurativa (search), with up to 71.4% of patients achieving at least 50% reduction in abscesses and inflamed skin bumps after 54 weeks.
The once-daily oral JAK1 (search) inhibitor showed superior convenience compared to current injectable treatments, with up to 57% of patients achieving major symptom reduction and 29% experiencing complete clearance of key skin lesions.
Regulatory applications for povorcitinib are currently under review by both the FDA and European Medicines Agency, potentially expanding treatment options for a condition affecting 1-4% of the U.S. population.
Incyte Corporation announced promising results from two late-stage clinical trials of povorcitinib, an experimental oral treatment for hidradenitis suppurativa (search), showing sustained symptom relief in patients with the painful chronic skin condition. The Delaware-based pharmaceutical company presented data at a medical meeting demonstrating that up to 71.4% of patients achieved at least 50% reduction in abscesses and inflamed skin bumps after 54 weeks of treatment.
Trial Results Show Sustained Efficacy
The studies evaluated povorcitinib in patients with moderate to severe hidradenitis suppurativa (search), a chronic skin disease that causes painful lumps, abscesses and scarring, typically in areas where skin rubs together such as the armpits or groin. After 54 weeks of treatment, the trials demonstrated significant clinical improvements across multiple measures.
Beyond the primary endpoint, the research showed that up to 57% of patients achieved major symptom reduction, while up to 29% experienced complete clearance of key skin lesions. These results suggest povorcitinib may offer substantial therapeutic benefits for patients suffering from this debilitating condition.
Mechanism and Treatment Advantages
Povorcitinib functions as a once-daily oral medication that works by blocking JAK1 (search), a protein involved in the inflammation that leads to painful abscesses and nodules characteristic of hidradenitis suppurativa (search). This oral formulation represents a potential advancement over current treatment options, which are mainly injectable drugs.
The convenience of oral administration could significantly improve patient compliance and quality of life compared to existing therapies. Currently, three FDA-approved treatments are available for the condition: AbbVie (search)'s Humira, Novartis' Cosentyx, and UCB (search)'s Bimzelx, all of which require injection.
Safety Profile and Patient Population
The most frequent side effects reported in the trials were acne, nasopharyngitis, and upper respiratory tract infections, according to Incyte. This safety profile appears manageable and consistent with other JAK inhibitors in clinical use.
Hidradenitis suppurativa (search) affects approximately 1% to 4% of people in the United States and has a higher impact on people from racial and ethnic minority groups, according to the U.S. Food and Drug Administration. The condition represents a significant unmet medical need, with limited treatment options currently available for patients.
Regulatory Timeline
Incyte has submitted applications seeking approval of povorcitinib to both the FDA and the European Medicines Agency, with reviews currently underway. The positive long-term efficacy data from these late-stage trials could support regulatory approval and provide a new treatment option for patients with moderate to severe hidradenitis suppurativa (search).
The sustained symptom relief demonstrated over 54 weeks of treatment suggests povorcitinib may offer durable therapeutic benefits, potentially addressing the chronic nature of this painful skin condition that significantly impacts patients' quality of life.